JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Jasper Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.48−0.00 (-0.52%)
Close on Oct 19, 2026
- Market cap
- $13.70M
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about Jasper Therapeutics from other investors
No posts about JSPR yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.